Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer

Miller P. et al, (2023), Cell Death & Differentiation, 30, 1619 - 1635

Regulation of immunological tolerance by the p53-inhibitor iASPP

Akama-Garren EH. et al, (2023), Cell Death & Disease, 14

Mutant Ras and inflammation-driven skin tumorigenesis is suppressed via a JNK-iASPP-AP1 axis

Al Moussawi K. et al, (2022), Cell Reports, 41, 111503 - 111503

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies

Freedman JD. et al, (2017), EMBO Molecular Medicine, 9, 1067 - 1087

ASPP2 deficiency causes features of 1q41q42 microdeletion syndrome

Zak J. et al, (2016), Cell Death & Differentiation, 23, 1973 - 1984